DKK1 and cholangiocarcinoma: In the registered clinical trials, we found DKK1 antibody DKN-01 had been entered into clinical phase I or phase II trial in advanced biliary tract cancer 7, advanced liver cancer, cholangiocarcinoma, gastric cancer and other tumors, and completed a promising study in gastric/gastroesophageal junction cancer3,33.